We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 18, 2019

Combination Gemcitabine Plus S-1 Noninferior to Gemcitabine Plus Cisplatin for Advanced/Recurrent Biliary Tract Cancer

Annals of Oncology


Additional Info

Annals of Oncology
Combination Gemcitabine Plus S-1 Versus Gemcitabine Plus Cisplatin for Advanced/Recurrent Biliary Tract Cancer: The FUGA-BT (JCOG1113) Randomized Phase III Clinical Trial
Ann. Oncol 2019 Sep 30;[EPub Ahead of Print], C Morizane, T Okusaka, J Mizusawa, H Katayama, M Ueno, M Ikeda, M Ozaka, N Okano, K Sugimori, A Fukutomi, H Hara, N Mizuno, H Yanagimoto, K Wada, K Tobimatsu, K Yane, S Nakamori, H Yamaguchi, A Asagi, S Yukisawa, Y Kojima, K Kawabe, Y Kawamoto, R Sugimoto, T Iwai, K Nakamura, H Miyakawa, T Yamashita, A Hosokawa, T Ioka, N Kato, K Shioji, K Shimizu, T Nakagohri, K Kamata, H Ishii, J Furuse

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading